Analysts See $-0.19 EPS for Affimed N.V. (AFMD)

March 19, 2018 - By Lynda A. Deweese

 Analysts See $ 0.19 EPS for Affimed N.V. (AFMD)

Analysts expect Affimed N.V. (NASDAQ:AFMD) to report $-0.19 EPS on March, 29.They anticipate $0.02 EPS change or 11.76 % from last quarter’s $-0.17 EPS. After having $-0.21 EPS previously, Affimed N.V.’s analysts see -9.52 % EPS growth. The stock decreased 4.44% or $0.1 during the last trading session, reaching $2.15. About 507,529 shares traded. Affimed N.V. (NASDAQ:AFMD) has declined 19.09% since March 19, 2017 and is downtrending. It has underperformed by 35.79% the S&P500.

Affimed N.V. (NASDAQ:AFMD) Ratings Coverage

Among 8 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Affimed Therapeutics had 17 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Sell” rating by Zacks given on Monday, August 10. As per Thursday, August 6, the company rating was maintained by Oppenheimer. The stock of Affimed N.V. (NASDAQ:AFMD) earned “Hold” rating by Jefferies on Monday, June 12. Leerink Swann downgraded the shares of AFMD in report on Thursday, May 19 to “Market Perform” rating. As per Tuesday, August 1, the company rating was maintained by Oppenheimer. The firm has “Hold” rating by Zacks given on Thursday, September 3. The stock has “Hold” rating by Jefferies on Thursday, May 19. The firm has “Outperform” rating given on Tuesday, April 12 by BMO Capital Markets. Laidlaw initiated the shares of AFMD in report on Thursday, December 10 with “Buy” rating. As per Friday, December 4, the company rating was initiated by Wells Fargo.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $130.43 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

More recent Affimed N.V. (NASDAQ:AFMD) news were published by: which released: “What’s Happening with These Biotech Stocks? — Aeterna Zentaris, Affimed …” on March 13, 2018. Also published the news titled: “Affimed Announces Fourth Quarter and Year End 2017 Financial Results and …” on March 13, 2018.‘s news article titled: “Affimed Appoints Dr. Leila Alland as Chief Medical Officer” with publication date: March 19, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.